stella
beta
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation — Stella
Recruiting
Back to Acute Myeloid Leukemia With FLT3/ITD Mutation trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(3 sites)
United States
UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Ohio State University Comprehensive Cancer Center, Columbus, Ohio
University of Pennsylvania, Philadelphia, Pennsylvania
View full record on ClinicalTrials.gov